Form 4: Adaptive Biotechnologies Exec Trades Shares

Sharon Benzeno, Chief Commercial Officer of Adaptive Biotechnologies Corp, reported a series of stock transactions on June 26-29, 2026, including acquisitions and dispositions of common stock and stock options.

Summary

• Sharon Benzeno, Chief Commercial Officer of Adaptive Biotechnologies Corp, executed several transactions involving common stock and stock options between June 26 and June 29, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 12, 2025.
• The reporting person acquired shares at prices ranging from $3.99 to $12.14 and disposed of shares at prices ranging from $21.00 to $21.38.
• Following these transactions, Benzeno's beneficial ownership of common stock stands at 221,278 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it details significant stock transactions by an executive, the use of a Rule 10b5-1 plan indicates a pre-determined strategy rather than a reaction to new information.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured approach to managing personal holdings.
• Acquisition of shares at lower prices ($3.99 - $12.14) and disposition at higher prices ($21.00 - $21.38) suggests profitable trades.
• The reporting person continues to hold a significant number of shares (221,278) after the reported transactions.

Negatives

• A significant number of shares were disposed of, potentially indicating a reduction in the executive's direct stake in the company.
• The weighted-average sale prices, while higher than acquisition prices, are within a relatively narrow range, suggesting a controlled exit strategy rather than a significant market upswing.

Risks

• The Rule 10b5-1 plan implies a pre-determined strategy for selling shares, which could be influenced by factors not immediately apparent in the filing.
• While not explicitly stated as a risk, the disposition of a substantial number of shares by a key executive could be interpreted negatively by the market if not accompanied by clear strategic rationale.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025.
• The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
• The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a Rule 10b5-1 plan by Adaptive Biotechnologies Corp's Chief Commercial Officer is a common practice for executives to diversify or manage their holdings in a pre-planned, non-insider-trading-violating manner.

Stakeholder Impact

• Shareholders: The disposition of shares by a key executive might be perceived as a negative signal, although the Rule 10b5-1 plan mitigates concerns about insider trading.
• Employees: The transactions do not directly impact employee stock options or benefits.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The reporting person may continue to execute transactions under the Rule 10b5-1 plan.
• The company may be requested to provide further details on specific sale prices within the reported ranges.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Rule 10b5-1, Adaptive Biotechnologies Corp, ADPT, Sharon Benzeno, Common Stock, Beneficial Ownership